RxDoctor Payments Data

Shawn Thomas, OD

Optometrist · Murrells Inlet, SCNPI 1295736445

Payments from drug & device makers

$3,191in general payments, 2019–2025

Across 49 payments — averaging $65.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Bausch & Lomb Americas Inc.$488
  • Coopervision Inc.$206
  • Notal Vision, Inc.$170
  • Alcon$165
  • Shire North American Group Inc$140
  • plus $662 from 13 others

What the payments were for

  • Travel & lodging$1,10535%
  • Food & beverage$2,08665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,191 in reported general payments places this provider in the 80th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$421,412
Medicare patients
2,061
Services billed
5,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost43$34,632
RestasisCyclosporine17$29,332
MieboPerfluorohexyloctane/Pf29$22,892
Prednisolone Acetate425$20,507
Cyclosporine16$11,771
Brimonidine Tartrate80$4,748
Latanoprost317$4,483
Lotemax SmLoteprednol Etabonate17$4,233
Doxycycline Hyclate184$3,752
Travoprost15$2,680
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat146$2,128
Timolol Maleate100$1,926
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha133$1,655
Loteprednol Etabonate11$1,374
Fluorometholone11$1,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$86$63,96460 claims
Bausch & Lomb Americas Inc.Miebo$488$22,89229 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$31$5,60728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →